Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.0136 | 0.236 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0526 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.0136 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0024 | 0.0112 | 0.0097 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.0136 | 0.0121 |
Echinococcus multilocularis | tumor protein p63 | 0.0347 | 0.5163 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.0136 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0112 | 0.1888 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0024 | 0.0112 | 0.0097 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0051 | 0.0526 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.0656 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.0136 | 0.0121 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0085 | 0.1064 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0085 | 0.1064 | 1 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.0656 | 1 | 1 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0656 | 1 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0.0136 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0.0136 | 0.5 |
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0024 | 0.0112 | 0.0097 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0024 | 0.0112 | 0.0097 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.0656 | 1 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0024 | 0.0112 | 0.0097 |
Echinococcus granulosus | tumor protein p63 | 0.0347 | 0.5163 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0112 | 0.1888 |
Onchocerca volvulus | 0.0051 | 0.0526 | 1 | |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0024 | 0.0112 | 0.5 |
Mycobacterium tuberculosis | Fatty-acid-AMP ligase FadD30 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) | 0.0018 | 0.0016 | 0.0016 |
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0024 | 0.0112 | 0.0112 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0085 | 0.1064 | 1 |
Brugia malayi | hypothetical protein | 0.0026 | 0.0136 | 1 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.0656 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0024 | 0.0112 | 0.1888 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0024 | 0.0112 | 0.0097 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0024 | 0.0112 | 0.0097 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.0656 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.0656 | 1 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0.0136 | 0.5 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0024 | 0.0112 | 0.0112 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0024 | 0.0112 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0085 | 0.1064 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.0136 | 0.0121 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0085 | 0.1064 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0024 | 0.0112 | 0.0097 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.